Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Purchased by Forbes J M & Co. LLP

Forbes J M & Co. LLP raised its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 56.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,094,564 shares of the company's stock after purchasing an additional 392,832 shares during the quarter. Forbes J M & Co. LLP owned 1.89% of Ginkgo Bioworks worth $6,239,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. KLP Kapitalforvaltning AS bought a new position in Ginkgo Bioworks during the 4th quarter worth approximately $46,000. CWM LLC lifted its holdings in shares of Ginkgo Bioworks by 667.6% in the 1st quarter. CWM LLC now owns 12,274 shares of the company's stock worth $70,000 after purchasing an additional 10,675 shares during the last quarter. Green Alpha Advisors LLC lifted its holdings in shares of Ginkgo Bioworks by 31.7% in the 1st quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock worth $105,000 after purchasing an additional 4,449 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Ginkgo Bioworks in the 4th quarter worth approximately $116,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Ginkgo Bioworks by 14.4% in the 1st quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company's stock worth $150,000 after purchasing an additional 3,331 shares during the last quarter. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Trading Up 18.2%

Shares of NYSE DNA opened at $13.38 on Wednesday. The company has a market cap of $783.19 million, a price-to-earnings ratio of -1.46 and a beta of 1.48. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $16.85. The stock's 50 day simple moving average is $9.11 and its 200 day simple moving average is $9.16.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The company had revenue of $48.32 million during the quarter, compared to the consensus estimate of $38.70 million. Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. As a group, equities analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.